The probe will ablate cardiac tissue while a patient is undergoing a primary cardiac surgical procedure, such as coronary artery bypass grafting (CABG) or mitral valve (MV) replacement and/or repair and as part of the Maze procedure.
Accurate lesion placement and tissue preservation
Freezing preserves tissue integrity. SurgiFrost10 features a malleable probe shaft and flexible tip with adjustable insulation sleeve that allows an ablation zone between 25 and 100 mm.
The cryoprobe's flexibility and adjustability make for accurate lesion placement, minimizing inadvertent tissue damage.
This cold-energy system - which reaches temperatures as low as -160ºC - also minimizes the risk of endocardial thrombus associated with heat-based energy sources.
The tip adheres to the target site when freezing begins for precise lesion positioning on a beating heart. The SurgiFrost 10 system combines the traditional safety of cryoenergy with the speed and flexibility required by today's cardiothoracic surgeons.
A versatile choice
The SurgiFrost 10 CryoSurgical Ablation System is quick and easy to set up and the probe is flexible and easy to manoeuvre.
Its 100-mm segment can be configured to desired lengths and shapes to produce ideal ablation lines.
SurgiFrost 10 can be used with all incision types and in conjunction with any cardiac surgical procedure.
Full median sternotomy, small sternal incisions and thoracotomy.
It can be used in a beating or arrested heart to perform all generally accepted lesion sets, including completing all Maze lesion lines efficiently.
Life Systems Medical | Cardioverter Defibrillators, Cardiac Pacemakers, Holter Monitors & Cardiac Ablation Systems
Life Systems Medical is an Australian company committed to providing it's customers with the most advanced medical device solutions available worldwide.
Our products range from highly effective coronary and vascular solutions to industry leading implantable hearing devices.The products range from highly effective coronary and vascular solutions to high tech laser technology for the treatment of coronary and vascular disease. They specialize in bringing to Australia new and innovative medical solutions and commit to providing advanced products while ensuring safety and efficacy.
Life Systems are pleased to announce TGA approval of the Watchman LAA Cardiac Occluder. The groundbreaking implantable device offers a safe alternative to warfarin therapy for patients at risk of stroke.
Our philosophy is to provide the most advanced products while ensuring safety and efficacy. We provide a life long commitment to Australian patients with responsive personal service.